Wayground logo

Free Printable Worksheets

Font size

S
M
L
XL
Worksheets

CSE Prep

Total questions: 68

Worksheet time: 1hrs 21mins

Name
Class
Date
1.

Pathology

a)

Weakened, enlarged airspace’s often along with an increase in goblet cells and mucus gland

1.

COPD

b)

Chronic inflammatory/obstructive disease known for exacerbations of wheezing and coughing

2.

Asthma

c)

Thick tenacious mucus accumulation in the lungs, blocks passageway of the pancreas and prohibits enzymes from reaching intestine.

3.

Cystic fibrosis

d)

Gas or free air in the pleural space

4.

Pathology of pneumothorax

e)

Abnormal condition that affects cardiac pumping caused by MI, ischemic heart disease or cardiomyopathy

5.

CHF/pulmonary edema

2.

Pathology

a)

An increase in mean pulmonary artery pressure greater than 25 at rest usually due to COPD or ILD

1.

Pulmonary hypertension, PH

b)

Interruption of coronary blood flow for an extended period causing potentially irreversible damage to the heart muscles

2.

Myocardial infarction/ischemia

c)

Chronic disorder of neuromuscular junction resulting in descending paralysis

3.

Myasthenia gravis

d)

Autoimmune disorder of the peripheral nervous system

4.

Guillian-barre syndrome

e)

Portion of brain loses blood supply as a result of a vascular occlusion or hemorrhage

5.

Stroke/cerebral infrc, CVA

3.

Pathology

a)

Acute illness or injury to the lungs that results in reduced lung compliance, diffuse Atelectasis, and refractory hypoxemia

1.

ARDS

b)

Failure of the cardiovascular system to adequately perfume tissues resulting in an impairment of cellular metabolism: reduction in blood flow to the tissues

2.

Shock

c)

Decrease renal function secondary to diabetes Mellitus or renal insufficiency

3.

Diabetes/renal failure

d)

Not enough surfactant or depressed surfactant leading to Atelectasis and hypoxemia

4.

Infant RDS, hyaline membrane disease

e)

Overuse of medication that exceeds the recommended dose

5.

Drug overdose

4.

Pathology: Muscular Dystrophy

A group of genetic disorders that cause progressive weakness and degeneration of the muscles that control movement.

a)

Bacterial infection that affects the nervous system, causes muscle stiffness and spasms (jaw/neck muscles)

1.

Tetanus

b)

Viral infection, genetics, puncture wound

2.

Etiology

c)

History of present illness, current medications

3.

Assessment

d)

Establish airway, monitor VT, VC, MIP, O2,

4.

Treat

5.

Pneumonia

a)

CXR, CBC, sputum culture

1.

Diagnostic

b)

O2, pulmonary hygiene therapy, hyperinflation (IS/SMI, IPPB), MV, VAP protocol

2.

Treat

c)

Penicillin G, amoxicillin

3.

Drugs

d)

S. Aureus (MRSA), treat with vancomycin . Cefotaxime, ceftriaxone, ciprofloxacin

4.

Penicillin resistant pathogen

6.

Acquired Immunodeficiency Syndrome, AIDS

a)

Virus attacks the immune system, gradually weakening it over time and making it difficult for the body to fight infections

1.

Pathology

b)

Frequent pneumonia, bronchitis, sinus/ear infections, Meningitis, low platelets counts or anemia

2.

History

c)

Drug cocktails, Antiretroviral, high activity antiretroviral therapy

3.

Treatment

d)

Trimethoprim and sulfamethoxazole, corticosteroids within 72 hrs

4.

Pneumocystis carinii pneumonia, PCP

7.

Accumulation of blood in the pleural space

a)

Pathology

Hemothorax

b)

General appearance

Cyanosis, tracheal shift away from from affected side, productive cough (hemoptysis), dull percussion

8.

COPD Medications

a)

SABA:

Albuterol, xopenex, ipratropium

b)

LABA:

Salmeterol, spirivia

c)

Steroids:

Fluticasone, budesonide

d)

Combination MDIs:

Advair, symbicort

e)

First line treatment: especially in exacerbations

LAMAs, tiotropium (spirivia), Glycopyrrolate (Seebril), umeclidinium (incruse), aclidinium.

9.

Outpatient COPD

a)

Spirometry, ABG, review therapy (meds/techniques), psychological (support system, depression), cessation of smoking (done prior to rehab), avoid secondhand smoke

1.

F/U exam: 3-4 weeks

b)

SABA, LABA, Steroids, Combo MDI

2.

Medications

c)

Controlled lip pursed breathing, I/S, coughing, diet and exercise

3.

Other

d)

4.

GOLD

e)

5.

COPD classification

10.

Pathology: CBABE

a)

You know this

1.

CF

b)

Obstructive condition p, irreversible damage of bronchial walls (excessive inflammation) , copious amounts of bronchial secretions, commonly limited to lobe or segment

2.

Bronchiectasis

c)

Reoccurring episodes of dyspnea, wheezing, chest tightness

3.

Asthma

d)

Increased mucus production in trachea and bronchi, productive cough that lasts at least 3 months of the year

4.

(Chronic) bronchitis

e)

Increased lung expansion due to air trapping, irreversible damage to alveolar walls, enlargement of air spaces

5.

Emphysema

11.

Pathology: Adult Cardiovascular

a)

Sudden, rapid decline in heart functioning and the amount of blood your heart can pump to the rest of the body. (Lower left chamber, left ventricle)

1.

Acute heart failure, AHF

b)

Occurs as a result of damage to the right side of heart , resulting from pulmonary hypertension. Increased right ventricular workload that causes hypertrophy of the RV. Often caused by COPD

2.

Cor pulmonale

c)

When the arteries that supply blood to the heart become narrowed or blocked, which can restrict blood flow and oxygen to the heart muscle. Caused by atherosclerosis

3.

Coronary artery disease

12.

Pathology: Adult Cardiovascular

Pulmonary Embolus

a)

Ventilation without perfusion

1.

Pulmonary Embolus

b)

Anxious, diaphoretic, cyanotic, cool/clammy, SOB, tachypnea, wheezing/crackles/pleural friction rub, possible hemoptysis, sudden onset of signs/symotoms

2.

Assessment

c)

CXR: increased density in infarcted area, wedge shape infiltrate. Hemodynamic: increased PAP. Capnography: decreased PeCO2, normal PaCO2. VD/VT: increased.

3.

Diagnostic testing

d)

1)Spiral CT -most sensitive,

2)V/Q scan, 3)Pulmonary angiogram

4.

Special tests

e)

5.

Treatment

13.

Thermal Lung Injury

a)

Tachypnea and cough may be productive of thick black sooty secretions

1.

Respiratory pattern

b)

Normal in early stages, may present with wheezes, crackles, or rhonchi, inspiratory strider

2.

Breath sounds

c)

100% NRB, IF severe, establish an airway FIRST. CPAP to minimize pulmonary edema. Burn injuries determined by bronchoscopy,

3.

Treatment

14.

Pediatric Pathology

a)

A viral infection characterized by inflammation of the bronchioles that results in wheezing and difficulty breathing in children

1.

Bronchiolitis

b)

Viral infection of the upper airways that results in subglottic swelling and an obstruction below the vocal cords. Results in stridor.

2.

Croup

c)

Acute upper airway infection that causes severe supraglottic swelling.

3.

Epiglottitis

d)

Chronic respiratory disorder in premature and low birth weight infants characterized by a reduction in the overall surface area for gas exchange (results from the treatment of RDS with MV and high O2 over a prolonged period of time >28 days)

4.

Bronchopulmonary dysplasia

15.

Pediatric Pathology: Croup

a)

Cough-barking, stridor, hoarse voice, nasal flaring, rhinorrhea, substernal/intercostal retractions, cyanosis

1.

Assessment

b)

O2 (24-28% initially), ABG

2.

Diagnostic

c)

Racemic via SVN, corticosteroids (decadron) when unresponsive to epi, MV

3.

Drugs

16.

Pediatric Pathology: Epiglottitis

a)

2-6yrs, pale, cyanotic, lifeless, drooling, hoarseness, dysphagia, tongue thrust forward during inspiration, diminished BS with inspiratory stridor.

1.

Assessment

b)

Visualization of pharynx, oral temp, ABG, IV, Neck X-ray

2.

DO NOT DO-avoid stimulation

c)

24-36hr initially

3.

Intubation

d)

Lateral neck X-ray (after sedation) will show thumb sign

4.

Confirmation of diagnosis

17.

Pediatric Pathology: Bronchiolitis

a)

Nasal discharge, lethargic, nasal flaring, cyanosis

1.

Assessment

b)

Tachypnea, apnea in severe cases, grunting, retractions, wheeze, upper airway noise from secretions

2.

Respiratory

c)

Plenty of fluids, oral decongestants, clearance of secretions from nasal passages

3.

Treatment: Home

d)

(Severe symptoms: apnea, CHD, CF, BPD, asthma)

O2 with humidity, aerosolized bronchodilators, IV fluids, bronchial hygiene

4.

Treatment: Hospital

18.

Pediatric Pathology: BPD

a)

Early surfactant replacement therapy

1.

PRIORITY

b)

Prevents atelectasis and intubation

2.

Non invasive CPAP

c)

Bronchodilators, diuretics or fluid management (monitor input) vaccines for RSV and influenza

3.

Drugs

d)

To prevent infection

4.

Radiant warmer

19.

Treatment for adult cardiovascular

a)

O2, CPAP for pulmonary edema/hypoxemia, NPPV for impending respiratory failure: first line For persistent hypoxia, unresponsive to O2, increased WOB (hallmark signs)

1.

AHF

b)

O2, monitor vital signs, treat underlying cause, decrease workload by lowering PAP. Digitalis, diuretics, nitric oxide

2.

Cor Pulmonale

c)

Minimize risk factors, if angina: O2, nitroglycerin, angioplasty/stent, CABG

3.

Coronary artery disease, CAD

d)

Cessation of smoking, limit cholesterol/fats, exercise, Control BP and aspirin for blood thinner

4.

Minimize risk factors for CAD

20.

Treatment of Emphysema / Chronic bronchitis

a)

SABA, LABA, anticholingeric, LAMA, ICS, Antibitoics (indicated by sputum)

1.

Medication

b)

Low flow O2, NPPV for acute exacerbations of ventilator failure (ph: <7.35, CO2: >45)

2.

General Management

c)

Nutrition, exercise, method to aid in secretions, home O2 and aerosol therapy.

3.

Outpatient rehab/home care

21.

What patient type is characterized by:

Chronic lung disease, dyspnea, increased AP with obstructive lung disease, distended neck veins, chest pain, peripheral edema, and clinical manifestation appear during exercise testing

a)

Cor pulmonale

b)

CHF

c)

Coronary artery disease

22.

What patient type is characterized by:

Barrel chest, clubbing of fingers, cyanosis, use of accessory muscles, and expiratory wheeze only

a)

COPD

b)

ARDS

c)

Asthma

d)

CF

23.

What patient type is characterized by:

Pursed lip breathing, prolonged exhalation, chest tightness, use of accessory muscles, increased AP during episode, pulses paradoxes (severe)

a)

Asthma

b)

COPD

c)

Pneumothorax

24.

What patient type is characterized by:

Barrel chest, cyanosis, clubbing, thick viscous mucus accumulation

a)

CF

b)

Thermal lung injury

c)

CHF

25.

What patient type is characterized by:

cyanosis, tracheal or mediastinal shift away from affected side, bruising over affected area

a)

Pneumothorax

b)

COPD

c)

CHF

26.

What patient type is characterized by:

Anxious, surface burns, black soot marks, cyanosis (cherry red CO2)

a)

TLI/Smoke inhalation/CO poisoning

b)

PH

c)

COPD

27.

What patient type is characterized by:

Peripheral/pedal edema, diaphoresis, cyanosis, tachyonea, orthopnea, crackles and wheezing, pink frothy secretions

a)

CHF/pulmonary edema

b)

pulmonary Hypertension, PH

c)

MI

28.

What patient type is characterized by:

Anxious, diaphoretic, cyanosis, peripheral edema, jugular vein distension

a)

CHF

b)

Pulmonary hypertension

c)

Myocardial infarction/ischemia

29.

What patient type is characterized by:

Diaphoretic, anxious, chest pain

a)

Myaocardial ischemia/infarction

b)

Pulmonary hypertension

c)

Pulmonary embolism

30.

What patient type is characterized by:

General weakness at rest/drooping eyes, double vision (diplopia) difficulty swallowing (dysphagia)

a)

Myasthenia gravis

b)

Guillian barre

31.

What patient type is characterized by:

Autoimmune weakness specially in legs, cyanosis, shallow breathing

a)

Myasthenia gravis

b)

Guillian barre

32.

What patient type is characterized by:

Slow shallow, respiration/diminished breath sounds, altered level of consciousness, euphoria

a)

Drug overdose

b)

Stroke, acute brain attack, cerebral infarction, cerebral vascular accident

(CVA)

33.

What patient type is characterized by:

Motor/speech loss, Cheyne-stokes

a)

Drug overdose

b)

Stroke, acute brain attack, cerebral infarction, cerebrovascular accident(CVA)

34.

What patient type is characterized by:

Cyanotic, tachypnea, substernal/intercostal retraction

a)

ARDS

b)

IRDS

35.

What patient type is characterized by:

Pale or cyanotic, cold, clammy, lethargic, unresponsive, diaphoretic, poor capillary refill

a)

Shock

b)

Diabetes/renal failure

36.

What patient type is characterized by:

Kussmauls, rales if CHF is present

a)

Diabetes/renal failure

b)

Drug overdose

37.

What patient type is characterized by:

cyanosis, GA <38, low APGAR scores, L:S <2:1

a)

IRDS/ Hyaline membrane disease (HMD)

b)

ARDS

38.

Initial settings for NPPV with AHF

If in cardiogenic shock: warfarin, thrombolytics, diuretics

a)

3-5 To get VT 6-8ml.. Lower volumes prevent compromise of venous return

1.

IPAP

b)

3-5, can increase 8-12 as tolersted

2.

EPAP

c)

Titrate to maintain >92%

3.

FiO2

d)

pH: <7.30, CO2: >50

4.

Intubation

e)

Nitride, diuretics, vaspressors (milrinonr)

5.

Drugs, fluid resuscitation

39.

Diagnostic Testing

a)

CXR: hyperinflation/increased AP

PFT: decrease volumes

ABG

1.

COPD

b)

Reduced peak flow, post-bronchodilator spirometry (increased by 12% or 200ml), bronchial provocation test (methacholine), significant decrease in FEV1 confirms this

2.

Asthma

c)

Atelectasis/fibrosis, staphyloccocus/haemophilus, sweat chloride test (>60)

3.

CF, mucoviscidosis

d)

CXR: Hyperlucensy, no vascular markings on affected side, ABG: Acute hyperventilation with hypoxemia

4.

Pneumothorax

e)

CXR: increased radiodensity, tracheal shift to the away. CBC: reduced RBC/Hb/Hct

5.

Hemothorax

40.

Diagnostic Testing

a)

CoHb levels measure with Co-oximetry or hemoximeter

1.

TLI, smoke inhalation, CO

b)

CXR: butterfly/bat wings, hemodynamics: increased PCWP and PAP, cardiac enzymes: high BNP

2.

CHF, Pulmonary edema

c)

Increased PAP, respiratory alkalosis w hypoxemia, CXR: enlarge pulmonary arteries

3.

Pulmonary Hypertension

d)

ECG: elevated T waves, elevated S-T segment, Cardiac enzymes: elevated troponin level

4.

Myocardial ischemia, infarction

e)

Tensilon test, electromyography, blood test for Ach receptor antibodies

5.

Myasthenia gravis

41.

Diagnostic Testing

a)

Lumbar puncture: high protein in CSF >500, abnormal electromyograph, elevated IgM immunoglobain leve,s

1.

Guillian Barre

b)

Drug toxicity

2.

Drug overdose

c)

CT/MRI, cerebral angiogram, elevated ICP (5-10 normal, treat >20)

3.

Stroke, CVA

d)

CXR: increased opacity/honeycomb or ground glass. PAP elevated with normal PCWP

4.

ARDS

e)

ABG: hypoxemia, hemodynamics: decreased CVP, PAP, PCWP, QT. Decreased urine output

5.

Shock

42.

Diagnostic Testing

a)

ABG: metabolic acidosis, Urine output: Less than 0.5L a day

1.

Renal failure/diabetes

b)

CXR: increased opacity/ground glass

2.

IRDS/hyaline membrane disease

c)

.

3.

.

43.

Outpatient Rehab/Home care: Asthma

a)

Developed asthma plan, and scheduled

1.

F/U exam

b)

ICS (fluticasone, pulmicort, azmacort, singulair) - most effective long-term therapy. Albuterol, servant (LABA only with ICS), advair/symbicort as combo MDI

2.

Medications

c)

Physical activity encouraged, temp/humidity control in home

3.

Environment

d)

Lung expansion therapy, PEFR daily: pre/post bronchodilators, PT education

4.

Other

44.

Treatment

a)

Low O2, bronchodilators (SABA, LABA, anticholingeric, LAMA) bronchial hygiene as needed, NPPV for acute exacerbation of ventilatory failure, rehab (if smoker), increased fluids

1.

COPD

b)

O2, duoneb, oral or IV corticosteroid, intubation for acute hypercapnic respiratory failure (pH:<7.30). With severe asthma: initial 4mL/kg VT

2.

Asthma, Acute

c)

Eliminate/minimize triggers, LABA, ICS, mast cell stabilizers (cromolyn sodium), leukotriene inhibitors (montelukadt, zafirlukast, zileuton)

3.

Asthma, Long-term

d)

Heliox, magnesium sulfate, subcutaneous epinephrine

4.

Adjunct therapy for asthma

e)

20% or less: bedrest 30 days, 20% or more: chest tube, unstable pt: needle aspiration

5.

Pneumothorax

45.

Treatment

a)

thoracentesis/chest tube drain, O2, hyperinflation therapy (IS/IPPB) after chest tube, MV with PEEP for ventilatory failure.

1.

Hemothorax

b)

100% O2, hyperbaric therapy, hyperinflation, aerosolized meds (bronchodilators, mucolytics, corticosteroids), monitor ABG, electrolytes, fluids, bronchoscopy,

2.

TLI/CO

c)

High flow O2 with NRB, Fowler position, hyperinflation (IPPB, IPV), diutrietcs, analgesic morphine

3.

CHF/pulmonary edema

d)

O: oxygen

M: morphine

A: aspirin

N: nitroglycerin

4.

Myocardial Ischemia, infarction

e)

Monitor: Vt, VC, MIP.

MV as indicated, hyperinflation therapy, pulmonary hygiene

5.

Myasthenia Gravis

46.

treatment: myasthenia gravis

a)

Anticholinesterase (mestinon or prostigmine)

1.

Improve muscle strength

b)

Anticholinesterase - short duration: more suitable for diagnosis

2.

Tensilon

c)

Suctioning, intubation with MV with acute ventilatory failure

3.

Myasthenia crisis management

d)

Stimines (mestinon)

4.

Treatment

47.

Treatment of CHF

a)

Preload reduction agents: nitroglycerin, nitroprusside, morphine

b)

Antidysrhythmic agents:

-bradycardia: atropine

-tachycardia: procainamide, metoprolol

48.

Treatment of Myocardial infarction

a)

Antiarrhythmic drugs: amiodarone, procainamide, atropine

b)

Nitrates for chest pain

c)

Defibrillate: Pulseless ventricular tachycardia or ventricular fibrillation

49.

Treatment

a)

O2, IS/IPPB, pulmonary hygiene, deep breathing/coughing, CPT,

1.

Guillian barre

b)

100% O2 first, establish airway, Narcan, flumazenil (romazicon) for sedative (benzo), acetylcysteine for acetaminophen OD

2.

Drug overdose

c)

Anticoagulation therapy, vasodilators, thrombolytic therapy for acute ischemic stroke

3.

Stroke/ CVA

d)

O2, CPAP/PEEP, VT 6ml/plat less than 30, recruitment measures

PEEP can go as high as 30 or until cardiopulmonary compromise is seen (Optimal PEEP)

4.

ARDS

e)

MV, vasopressors (dopamine/dobutamine), inotropic agents for HF (digitalis), antibiotics, IV fluids for hypovolemia

5.

Shock

50.

Treatment

a)

O2, CPAP, neutral thermal environment, administer surfactant (calfactant, beractant)

1.

IRDS

b)

Bronchial hygiene therapy, O2, bronchodilators, mucolytic (dornase Alpha), inhaled antibiotics (TOBI)

2.

CF

c)

.

3.

.

51.

What are the six key points we like to discuss when it comes to educational program for families and close friends of patients with COPD? 1)​ (a)   2)​ ​ ​ (b)   3) ​ (c)   4) ​ (d)   5) ​ (e)  

Choose from the below words
nutritional management
recognize triggers
exercise program
methods to clear secretions
home O2 & aerosol therapy
52.

Asthma action plan

a)

GREEN: 80-100%

b)

YELLOW: 50-79%

c)

RED: < 50%

53.

Neonatal Resuscitation

Meconium Aspiration

a)

If meconium (first poop) is present, suction mouth and nose with a bulb syringe if the baby is____.

1.

Vigorous

b)

If meconium (first poop) is present, DO NOT suction mouth and nose if the baby is ___.

2.

Non-vigorous

c)

Initiate PPV if infant is not breathing OR

3.

If HR is less than 100

d)

HFOV, iNO, ECMO

4.

Other ventilation/oxygen therapies

e)

Antibiotics, steroids

5.

Drug therapy

54.

Neonatal Resuscitation

Meconium Aspiration

a)

1.

FiO2 target pre-ductal spO2 aft. Birth

b)

Start chest compressions when the HR remains at ___ despite of 30 seconds of effective PPV.

2.

Less than 60bpm

c)

3:1

3.

Compression/ventilation ratio

d)

Deliver___ compressions and ___ ventilation each minute.

4.

90/30

55.

Normal Values: CBC

a)

4-6

1.

RBC

b)

12-16

2.

Hb

c)

40-50%

3.

Hct

d)

5-10 (thousand)

4.

WBC

56.

Electrolytes

a)

135-145

1.

Na+, sodium

b)

3.4-4.5

2.

K+, potassium

c)

90-100

3.

Cl-, chloride

57.

Infant (Term)

a)

110-160

1.

HR

b)

60/40

2.

BP

c)

30-60

3.

RR

d)

3000g (3kg)

4.

Weight

e)

Normal: 7-10

Poor: 4-6

Emergency: 0-3

5.

APGAR (1 & 5 mins)

58.

Calculations

a)

20-40% (up to 60% on vent)

1.

VD/VT

b)

17-20%

2.

CaO2

c)

4-5%

3.

C(a-v)O2

d)

3-5% normal,

<20 acceptable, >20 bad

4.

Qs/Qt

59.

Hemodynamics

a)

93-94mmhg

1.

MAP

b)

2-6mm Hg

(4-12 cm h2O)

2.

CVP

c)

25/8 (mean: 13-14)

3.

PAP

d)

4-12

4.

PWP/PCWP

e)

1) 4-8

2) 2.5-4.0

5.

1) QT

2) CI

60.

Prevention

a)

1.

VAP

b)

2.

Infection control: Home care

c)

3.

Pulmonary Rehab

61.

Special procedures

a)

1.

Heliox

b)

2.

HBO

c)

3.

iNO

d)

4.

Appearance of pleural fluid

e)

5.

Pleural effusion

62.

Special procedures

a)

1.

BAL

b)

2.

Cardiopulmonary stress test

c)

3.

Cardioversion

d)

4.

Defibrillation

e)

5.

Chest tubes

63.

Mechanical Ventilation

a)

1.

Initial settings for infant

b)

2.

Vent patient monitoring

c)

3.

Spontaneous monitoring

d)

4.

Normal loop graphics

e)

5.

weaning

64.

NPPV

a)

1.

Indications

b)

2.

Contraindications

c)

3.

Initial settings

65.

Breathing Techniques

a)

1.

SMI, IPPB, aerosol therapy, etc

b)

2.

Patient position, oxygenation

c)

3.

IPPB

d)

4.

Bronchial hygiene therapy

e)

5.

PEP

66.

Breathing techniques with medication devices

a)

1.

MDI

b)

2.

DPI

c)

3.

BNP level in CHF, <100 normal

67.

ECG reading and treatment

a)

1.

A-Flutter

b)

2.

A-Fib

c)

3.

PVC

d)

4.

V-tach

e)

5.

V-flutter/Fib

68.

ECG reading and treatment

a)

1.

Asystole

b)

2.

Ischemia

c)

3.

Injury

d)

4.

Infarction